Mayne Pharma has expressed confidence after its recent US launch of Nextstellis (estetrol/drospirenone) 14.2mg/3mg oral contraceptive tablets. While the firm’s overall sales dipped by 6% in its financial first half, Mayne expects its recent and near-term launches, particularly key dermatology products, to help reverse the trend.
After last year’s US launch of Nextstellis (estetrol/drospirenone) 14.2mg/3mg oral contraceptive tablets, Mayne Pharma is anticipating significant upward momentum for its sales “despite the COVID-19 headwinds.”
“Nextstellis remains the company’s most significant commercial opportunity participating in the $3.4bn short-acting combined hormonal contraceptive market,” said Mayne as...
Video provides a powerful way to help you prove your point. When you click Online Video, you can paste in the embed code for the video you want to add. You can also type a keyword to search online for the video that best fits your document.
We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.
We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
